Innovative Long-Acting HIV Prevention Shot Nearing Regulatory Approval
A new long-acting HIV prevention injection, lenacapavir, is nearing FDA approval. It promises to improve adherence with biannual dosing and could significantly impact HIV prevention efforts in the US and globally.
A groundbreaking HIV prevention injection, known as lenacapavir, is anticipated to receive approval from the U.S. Food and Drug Administration (FDA) later this month. If approved, this long-acting shot would be administered biannually, potentially revolutionizing HIV prevention strategies. The medication has demonstrated promising results, especially in a study involving women and girls, where none of the participants who received lenacapavir contracted HIV, showcasing its high efficacy.
This success has significantly impacted Gilead Sciences, the pharmaceutical company behind the vaccine, leading to a 73% rise in its stock value over the past year. Johanna Mercier, Gilead’s chief commercial officer, highlighted the importance of such innovations, noting the challenges associated with daily pill regimens and emphasizing the opportunity for a long-lasting injectable alternative.
Currently, over 400,000 individuals in the United States rely on daily oral medication for HIV prevention, known as pre-exposure prophylaxis (PrEP), with Gilead projecting this number to surpass one million in the next decade. Surveys reveal a strong preference among users for injectable options, with 95% of over 500 PrEP users expressing willingness to switch from daily pills to a long-acting injection.
Sales of other long-acting PrEP options like GSK’s Apretude have also seen a significant increase, up 63% over the past year. However, Gilead faces key challenges, notably reaching underserved populations. Despite Black Americans accounting for 39% of new HIV cases, they represent just 14% of current PrEP users. Barriers such as stigma and lack of insurance further hinder access, with expanding Medicaid coverage seen as a critical step.
Moreover, some experts express concerns that the new injection might displace existing products like Descovy, which currently holds substantial market share. Nonetheless, Gilead aims to broaden the overall use of PrEP globally, working with governments and health organizations in the UK and low-income countries to raise awareness and improve distribution.
This development signals a significant advancement in HIV prevention, with potential to increase accessibility and adherence, reducing new infections worldwide. For more information on pre-exposure prophylaxis, refer to the National Institutes of Health.
[source: https://medicalxpress.com/news/2025-06-hiv-shot.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Arkansas Egg Producer Recalls Free-Range Brown Eggs Due to Salmonella Risk
Black Sheep Egg Company of Arkansas is recalling free-range brown eggs due to salmonella contamination detected during FDA inspections. Consumers are advised to discard affected eggs with specific best-by dates and UPC codes to prevent illness.
Addressing Childhood Chronic Pain: The Role of School Nurses in Management and Care
A significant portion of children suffer from chronic pain impacting their daily lives. Training school nurses and community health providers in pain management strategies offers a promising solution to improve access and long-term outcomes for affected children.
Urgent Call for Action to Minimize Children's Exposure to Plastic Chemicals
Recent studies highlight the long-term health risks for children exposed to chemicals in plastics, urging urgent policy and lifestyle changes to protect future generations.
Sugary Drinks May Promote Metastasis in Advanced Colorectal Cancer
New research links sugary drinks to increased risk of metastasis in advanced colorectal cancer through metabolic pathways, highlighting dietary and therapeutic implications.